Business Context and Reporting Period
This Form 8-K was filed by LIFECORE BIOMEDICAL, INC. on April 13, 2023. The report addresses a regulatory compliance issue regarding the company's listing status on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding a listing notice and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metric.
Material Changes
- Listing Non-Compliance: The company received a notification from Nasdaq indicating it is not in compliance with Listing Rule 5250(c)(1) due to a delay in filing its Quarterly Report on Form 10-Q for the period ended February 26, 2023.
- Trading Status: The notification has no immediate effect on the listing or trading of the company's common stock.
Outlook, Risks, and Management Commentary
- Compliance Plan: The company has 60 calendar days (until June 12, 2023) to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 days from the original due date (until October 10, 2023) to file the Form 10-Q.
- Management Action: Management states it is working diligently to complete the Form 10-Q and plans to file it as promptly as possible.
- Risks: Forward-looking statements highlight risks regarding the ability to respond to Nasdaq inquiries, regain compliance, and the possibility that filing the Form 10-Q may take longer than expected.
Investor Verification Checklist
- Verify the current status of the Form 10-Q for the period ended February 26, 2023.
- Monitor the deadline of June 12, 2023, for the submission of a compliance plan to Nasdaq.
- Review the attached press release (Exhibit 99.1) for additional details on the delisting notice.
- Check for any subsequent filings regarding the acceptance of the compliance plan or the actual filing of the overdue 10-Q.